- Q1 2024 Calliditas Therapeutics AB Earnings Call TranscriptMay 23, 2024kr122.2 (+7.19%)Earnings
- Q4 2023 Calliditas Therapeutics AB Earnings Call TranscriptFeb 21, 2024kr108.3 (+1.31%)Earnings
- Q3 2023 Calliditas Therapeutics AB Earnings Call TranscriptNov 07, 2023kr87.6 (-5.40%)Earnings
- Q2 2023 Calliditas Therapeutics AB Earnings Call TranscriptAug 17, 2023kr86.25 (-13.92%)Earnings
- Q1 2023 Calliditas Therapeutics AB Earnings Call TranscriptMay 16, 2023kr107.2 (-18.42%)Earnings
- Calliditas Therapeutics AB Nefigard Topline Data Presentation TranscriptMar 13, 2023
- Q4 2022 Calliditas Therapeutics AB Earnings Call TranscriptFeb 23, 2023kr107 (+16.49%)Earnings
- Calliditas Therapeutics AB Fireside Chat with Everest Medicines Ltd TranscriptDec 14, 2022
- Q3 2022 Calliditas Therapeutics AB Earnings Call TranscriptNov 14, 2022kr78.9 (+0.96%)Earnings
- Calliditas Therapeutics AB KOL Webinar TranscriptNov 08, 2022
- Q2 2022 Calliditas Therapeutics AB Earnings Call TranscriptAug 18, 2022kr91.8 (-15.55%)Earnings
- Q1 2022 Calliditas Therapeutics AB Earnings Call TranscriptMay 18, 2022kr79.6 (+7.49%)Earnings
- Q4 2021 Calliditas Therapeutics AB Earnings Call TranscriptFeb 24, 2022kr81.3 (-6.12%)Earnings
- Calliditas Therapeutics AB -FDA Approval of TARPEYO to Reduce Proteinuria in IgA Nephropathy TranscriptDec 16, 2021
- Q3 2021 Calliditas Therapeutics AB Earnings Call TranscriptNov 18, 2021kr80 (+8.25%)Earnings
- Q2 2021 Calliditas Therapeutics AB Earnings Call TranscriptAug 19, 2021kr96.5 (-1.63%)Earnings
- Q1 2021 Calliditas Therapeutics AB Earnings Call TranscriptMay 18, 2021kr120.8 (+0.50%)Earnings
- Calliditas Therapeutics AB (publ) - Special Call TranscriptMar 10, 2021
- Q4 2020 Calliditas Therapeutics AB Earnings Call TranscriptFeb 18, 2021kr128.6 (-3.02%)Earnings
- Calliditas Therapeutics AB Corporate Analyst Meeting TranscriptJan 20, 2021
- Q3 2020 Calliditas Therapeutics AB Earnings Call TranscriptNov 12, 2020kr145.8 (-4.58%)Earnings
- Calliditas Therapeutics AB (publ) - Special Call TranscriptNov 09, 2020
- Q2 2020 Calliditas Therapeutics AB Earnings Call TranscriptAug 13, 2020kr103 (+2.39%)Earnings
- Q1 2020 Calliditas Therapeutics AB Earnings Call TranscriptMay 14, 2020kr92.5 (-9.49%)Earnings
Q4 2021 Calliditas Therapeutics AB Earnings Call Transcript
()-
Welcome to this Q4 report. With me today, I have Andrew Udell, President, North America; Chris Ngai, VP, Market Access; Fredrik Johansson, Chief Financial Officer.
I'd like to draw your attention to the disclaimer page on Page 2. With regards to any forward-looking statements made, I refer you to the company's reports and other filings, including those which contain risk factors and other relevant information.
Please turn the page to Page #3. So this quarter, Calliditas has achieved a historic milestone in the company's history as we had our first commercial product approved in the U.S. under accelerated approval by the FDA. This is the result of our pioneering efforts in IgA nephropathy, which started over a decade ago, and we are delighted to be able to offer the first and only approved drug to this highly deserving patient population. The actual approval was provided on December 15, and this is under the branding of TARPEYO. And as I mentioned, it's the accelerated approval
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)